On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.

On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.